Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless – Motley Fool
The Biological SCENE |
Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless
Motley Fool What’s all the fuss about? The big-ticket item is that this journal article reported that most humans probably have pre-existing immune defenses against the “cutting element” in CRISPR known as Cas9. If true, the CRISPR-Cas9 gene-editing system may be … CRISPR is coming to the clinic this year | January 8, 2018 Issue – Vol …The Biological SCENE Key CRISPR gene editing methods might not work for most humansEngadget 3 Soaring Gene-Editing Biotech Stocks: Which Is the Best Buy?Madison.com BBNS –Marea Informative (blog) all 9 news articles » |
Fort Wayne Journal Gazette |
Drawbacks of immunotherapy
Fort Wayne Journal Gazette When Diane Legg began seeing black specks in her right eye, she went to an ophthalmologist near her home in Amesbury, Massachusetts. He said she had a torn retina and needed laser surgery. Legg’s oncologist was skeptical. He was worried that Legg had … New medical treatments becoming problematicThe Japan News Growth Opportunities in Radioimmunotherapy Treatment Market: New Research Report 2017 – 2027satPRnews (press release) |
|
CRISPR is coming to the clinic this year
The Biological SCENE Since its conception in 2012, CRISPR gene editing has spurred headline-making breakthroughs in research labs. In 2018, though, some of CRISPR’s biggest firsts are likely to happen in the clinic. Three biotech firms, each partly founded by one of the … |
Boston Business Journal |
Pricey gene therapies expected to ‘dominate’ talk at JP Morgan conference
Boston Business Journal If you’re a biotech industry executive or investor, chances are you’re in San Francisco this week for the annual J.P. Morgan healthcare conference. And you can expect to hear plenty of lively discussion about gene therapies, a new class of drugs that … |